To get in touch with Biosynth, simply fill out the form below.
Subscribe to Supplier
Biosynth Bringing Large Scale and GMP Peptide Capabilities to Boulder Peptide Symposium 2023
Staad, Switzerland: – Peptide and Antibody manufacturer and developer Biosynth is returning for the fourth time to the annual Boulder Peptide Symposium (BPS) meeting in the USA, this time in California’s Napa Valley.
Biosynth is a co-sponsor of the event and a prominent exhibitor with a stand at Booth 13 at the Napa Valley Marriott Hotel conference venue, from where it will showcase its sophisticated GMP development and production capabilities.
Peptide design and synthesis
Dr. Maria Ufret, Vice President Operations at Biosynth Peptide Division will lead the company’s presence at BPS 2023. Her team will showcase the division’s ability to deliver excellence in peptide custom synthesis at small and large scale, as well as GMP manufacturing facilities. Biosynth has extensive experience in neoantigen peptides and library production and now operates out of four sites in the US and Europe.
Dr. Ufret commented “We have a well-established relationship with Boulder Peptide Symposium and have attended for the previous three years.”
“This is a superb event for the quality of the knowledge and insights shared here, as well as its opportunities to connect with peers and partners in a small venue setting, leading to meaningful conversations,” she added.
Biosynth is a multinational life sciences reagents, custom synthesis and manufacturing services enterprise that is playing a leading part in driving pharmaceutical and biotech innovation by supplying critical raw materials and services to the pharmaceutical and diagnostic industries as its core mission.
The Biosynth vision is to consolidate the highly fragmented and complex supply chain. Biosynth increases productivity of the pharmaceutical and diagnostics industries by improving availability and reducing time-to-market of new therapies and diagnostics assays, acting as a strategic partner to many leading pharma and biotech players.
Founded in 1966, Biosynth’s heritage and newly evolved multinational structure positions the company at the leading edge of innovation, able to combine chemistry with biology and products with services to construct a leading-edge research product portfolio comprising more than one million products.
Its end-to-end manufacturing services encompass fine chemicals, peptides and key biologics as part of a one-stop-shop overall offer.
Learn more at www.biosynth.com
About BPS 2023
The Boulder Peptide Foundation (BPF), headquartered in Boulder, Colorado, is a non-profit 501(3) corporation focused on public peptide therapeutics. The Society organizes the Annual Boulder Peptide Symposium as a key vehicle for driving the science and technology in this important field.
Founded in 2012, the BPS meeting is branded as the only conference solely focused on the pharmaceutical development of peptide therapeutics.
BPS 2023 is a four-day event opening September 18 at the Napa Valley Marriott Hotel & Spa, in the heart of California’s Napa vinery region.
BPS LIVE features a full program of presentations, workshops and poster sessions, is accompanied by Virtual BPS, an online platform for short, educational talk sessions that bring the latest in peptide research and clinical development to the scientific community.
The event is organised by the Boulder Peptide Foundation with further information at: www.boulderpeptide.org